PROTAC HDAC6/ERα degrader 1
PROTAC HDAC6/ERα degrader 1 is a dual-target PROTAC that targets HDAC6/ERα, with DC50 values of 1.21 μM (HDAC6), 0.28 μM (ERα) in MCF-7 cells and 0.67 μM (HDAC6), 0.14 μM (ERα) in LCC2 cells, respectively. PROTAC HDAC6/ERα degrader 1 selectively degrades ERα and HDAC6 via the proteasomal pathway, inhibits the transcriptional activation of ERα and blocks the estrogen signaling pathway. PROTAC HDAC6/ERα degrader 1 inhibits the function of HDAC6, attenuates hormone responses, and disrupts autophagy-lysosome function. PROTAC HDAC6/ERα degrader 1 induces cell cycle arrest, apoptosis and ferroptosis, and exhibits antiproliferative activity in breast cancer cells. PROTAC HDAC6/ERα degrader 1 can be used for breast cancer research.
(Pink: HDAC6 and ERα ligand (HY-187388); Blue: VHL ligand (HY-112078A); Black: linker).
For research use only. We do not sell to patients.
- CAS No.: 3092711-76-4
- Formula: C64H77F3N6O12S2
- Molecular Weight:1243.45
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All PROTACs Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
HDAC6 0.67-1.21 μM (DC50) |
ERα 0.14-0.28 μM (DC50) |
In Vitro
PROTAC HDAC6/ERα degrader 1 (V-12c) potently inhibits proliferation of ER+ and Tamoxifen (HY-13757A)-resistant breast cancer cell lines (MCF-7, LCC2, T47D, T47D ERαD538G, T47D ERαY537S) with IC50 values ranging from 0.23 μM to 1.23 μM, and shows low cytotoxicity in normal MCF-10A breast epithelial cells (IC50 >100 μM)[1].
PROTAC HDAC6/ERα degrader 1 (0.5-10 μM; 14 days) potently suppresses the colony-forming capacity of MCF-7 and Tamoxifen-resistant LCC2 breast cancer cells[1].
PROTAC HDAC6/ERα degrader 1 (0-50 μM; 24 h) selectively induces proteasome-dependent degradation of ERα and HDAC6 in MCF-7 and LCC2 breast cancer cells, with DC50 values ranging from 0.14 μM to 1.21 μM[1].
PROTAC HDAC6/ERα degrader 1 (50 μM; 30 min) directly binds to ERα and HDAC6 in breast cancer cell protein extracts, as demonstrated by increased thermal stability in CETSA assays[1].
PROTAC HDAC6/ERα degrader 1 (1-10 μM; 48-72 h) induces G1 phase cell cycle arrest in MCF-7 and Tamoxifen-resistant LCC2 breast cancer cells, accompanied by downregulation of key cell cycle regulatory proteins[1].
PROTAC HDAC6/ERα degrader 1 (5-20 μM; 72 h) induces apoptosis in MCF-7 and tamoxifen-resistant LCC2 breast cancer cells, with apoptotic proportions reaching 23.3−33.6% in MCF-7 (10−20 μM) and 27.0−30.1% in LCC2 (5−10 μM), accompanied by downregulation of the antiapoptotic protein Bcl-2[1].
PROTAC HDAC6/ERα degrader 1 (5 μM; 24-72 h) induces ROS-dependent ferroptosis in Tamoxifen-resistant LCC2 breast cancer cells, characterized by lipid peroxidation measured via MDA levels after 24 h, activation of the Nrf2-HMOX-1 pathway, and cytotoxicity that is partially reversed by ferroptosis and antioxidant inhibitors[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MCF-7, LCC2
-
Concentration:0-50 μM (dose-response); 1 μM (colocalization and proteasome inhibition experiments); 5 μM (carbobenzoxy-L-leucyl-L-leucyl-L-leucinal pretreatment)
-
Incubation Time:24 h (colocalization and proteasome inhibition experiments)
-
Result:Induced dose-dependent degradation of ERα and HDAC6 without affecting HDAC1, HDAC2, or HDAC4.
In MCF-7 cells, the DC50 was 0.28 μM for ERα and 1.21 μM for HDAC6; in LCC2 cells, the DC50 was 0.14 μM for ERα and 0.67 μM for HDAC6.
Degradation was blocked by pretreatment with the proteasome inhibitor carbobenzoxy-L-leucyl-L-leucinal.
Confirmed reduced ERα and HDAC6 levels in MCF-7 cells after treatment.
-
Cell Line:MCF-7, LCC2
-
Concentration:5-10 μM
-
Incubation Time:48 h
-
Result:Induced G1 phase arrest in both cell lines: in MCF-7 cells, G1 phase proportion increased to 86.8% (5 μM) and 84.9% (10 μM); in LCC2 cells, G1 phase proportion increased to 87.9% (5 μM) and 83.7% (10 μM).
Dose-dependently downregulated cell cycle regulatory proteins CyclinD1 and CDC2 in MCF-7 cells, and PCNA, CyclinD1, CDK2, and CDC2 in LCC2 cells.
-
Cell Line:MCF-7, LCC2
-
Concentration:10-20 μM (MCF-7 flow cytometry); 5-10 μM (LCC2 flow cytometry); 0-10 μM (Western blot)
-
Incubation Time:72 h (flow cytometry); 48 h (MCF-7 Western blot); 72 h (LCC2 Western blot)
-
Result:Dose-dependently increased apoptotic cell proportion: in MCF-7 cells, apoptotic cells reached 23.3% (10 μM) and 33.6% (20 μM); in LCC2 cells, apoptotic cells reached 30.1% (5 μM) and 27.0% (10 μM).
Dose-dependently downregulated antiapoptotic protein Bcl-2 in both cell lines, with no change in pro-apoptotic protein Bax.
In Vivo
PROTAC HDAC6/ERα degrader 1 (10 mg/kg; i.p.; every other day) potently suppresses tumor growth in Tamoxifen-resistant LCC2 breast cancer xenografts in female BALB/c nude mice, with an acceptable safety profile[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (female, breast cancer MCF-7 cell xenograft model)[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; every other day
-
Result:Reduced tumor volume and end-point tumor weight to levels superior to Ful and SAHA at the same dose.
Reduced the Ki67 proliferation index in tumor tissues.
Mediated potent proteasomal degradation of ERα and HDAC6 in tumor samples.
Exhibited no significant body weight fluctuations or histopathological evidence of cardiotoxicity, hepatotoxicity, or nephrotoxicity.
-
Animal Model:BALB/c nude (female, tamoxifen-resistant breast cancer LCC2 cell xenograft model)[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; every other day
-
Result:Inhibited tumor growth and reduced end-point tumor weight to levels superior to Ful and SAHA at the same dose.
Significantly reduced the Ki67 proliferation index in tumor tissues.
Downregulated ERα and HDAC6 protein levels in tumor samples.
Exhibited no toxic side effects or significant body weight fluctuations.
Chemical Information
-
CAS No. 3092711-76-4
-
Molecular Weight 1243.45
-
Formula C64H77F3N6O12S2
-
SMILES
FC(F)(F)CN(C1=CC=C(C=C1)OCCCCCCC(N[C@@H](C(C)(C)C)C(N2[C@@H](C[C@H](C2)O)C(N[C@@H](C3=CC=C(C4=C(C)N=CS4)C=C3)C)=O)=O)=O)S(=O)([C@@H]5[C@@]6([H])C(C7=CC=C(C=C7)NC(CCCCCCC(O)=O)=O)=C(C8=CC=C(C=C8)O)[C@](C5)([H])O6)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
-
Macroautophagy Solutions
Macroautophagy is a conserved lysosome-dependent degradation pathway in which cytoplasmic material is sequestered into double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. The pathway supports cellular homeostasis during nutrient limitation, organelle stress, protein-aggregate accumulation, infection, differentiation, and tissue remodeling by coupling cargo sequestration, autophagosome maturation, lysosomal fusion, and degradation of cargo-derived macromolecules. The core molecular sequence includes initiation by nutrient- and stress-regulated autophagy machinery, autophagosome nucleation, LC3/ATG8-family conjugation to autophagosomal membranes, cargo selection through receptors such as SQSTM1/p62, autophagosome-lysosome fusion, and lysosomal degradation. LC3 was identified as a mammalian homolog of yeast Atg8 that localizes to autophagosomal membranes after processing, and p62/SQSTM1 was shown to connect ubiquitinated cargo with autophagic degradati
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)